HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Topical application of recombinant platelet-derived growth factor increases the rate of healing and the level of proteins that regulate this response.

Abstract
A bipedicle ischaemic rat skin flap model was used to study the effects of daily topical applications of platelet-derived growth factor (PDGF) on the healing of ischaemic wounds. Levels of tumour necrosis factor-alpha (TNFA), interleukin 1-beta (IL1B) and both the latent and active forms of matrix metalloproteinase 2 (MMP2) and 9 (MMP9) were measured. Full-thickness wounds were made on a total of 72 adult male Sprague-Dawley rats. Each group of 18 rats with normal and ischaemic wounds received either vehicle or 0·01% recombinant PDGF-BB. Additional applications were made on the wounds on a daily basis. Wound areas were measured at 0, 1, 3, 5, 7 9 and 13 days after wounding. Ischaemia caused a delay in wound healing as well as an increase in TNFA, IL1B and both the pro and active forms of MMP2 and MMP9. PDGF accelerated the rate of wound healing in both normal and ischaemic wounds and negated the effect of ischaemia. PDGF reduced the TNFA concentration in both normal and ischaemic wounds, and the rate of wound healing closely resembled the pattern of TNFA protein expression. PDGF also reduced both the magnitude and duration of the increases in IL1B and both the pro and active forms of MMP2 and MMP9 induced by ischaemia.
AuthorsSantosh Gowda, David A Weinstein, Timothy D Blalock, Kavita Gandhi, Bruce A Mast, Gloria Chin, Gregory S Schultz
JournalInternational wound journal (Int Wound J) Vol. 12 Issue 5 Pg. 564-71 (Oct 2015) ISSN: 1742-481X [Electronic] England
PMID24118782 (Publication Type: Journal Article)
Copyright© 2013 The Authors. International Wound Journal © 2013 Medicalhelplines.com Inc and John Wiley & Sons Ltd.
Chemical References
  • Angiogenesis Inducing Agents
  • Interleukin-1beta
  • Proto-Oncogene Proteins c-sis
  • Tumor Necrosis Factor-alpha
  • Becaplermin
  • Matrix Metalloproteinase 2
  • Matrix Metalloproteinase 9
Topics
  • Administration, Topical
  • Angiogenesis Inducing Agents (therapeutic use)
  • Animals
  • Becaplermin
  • Disease Models, Animal
  • Interleukin-1beta (metabolism)
  • Ischemia (complications, metabolism)
  • Male
  • Matrix Metalloproteinase 2 (metabolism)
  • Matrix Metalloproteinase 9 (metabolism)
  • Proto-Oncogene Proteins c-sis (therapeutic use)
  • Rats
  • Rats, Sprague-Dawley
  • Tumor Necrosis Factor-alpha (metabolism)
  • Wound Healing (physiology)
  • Wounds, Penetrating (drug therapy, etiology, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: